Clinical Trial Update: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the DTaP-IPV-Hep B-PRP-T vaccine given with Prevenar and Rotarix in healthy Latin American infants; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTaP-IPV-Hep B-PRP-T vaccine (Pentaxim) (Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-PRP-T conjugate vaccine)
• Prevenar (pneumococcal conjugate vaccine)
• Rotarix (Rotavirus vaccine (live attenuated))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2014-05-05